More than 731,000 Americans have died from COVID-19 while over 4.9 million people have died from the disease worldwide, according to real-time data compiled by the Center for Systems Science and Engineering at Johns Hopkins University.
Just 66.9% of Americans ages 12 and up are fully vaccinated against COVID-19, according to data from the Centers for Disease Control and Prevention.
Your guide to booster eligibility
The Centers for Disease Control and Prevention have now signed off on boosters for all three COVID-19 vaccines authorized in the U.S., after Thursday's recommendation for the Moderna and Johnson & Johnson shots.
Unsure if you're eligible to receive any of them? Check out ABC News' handy guide.
Delta doesn't cause more severe illness than prior variants: CDC
A new report from the Centers for Disease Control and Prevention suggests that although the delta variant is significantly more transmissible than prior variants, it is not more likely to lead to hospitalization.
Instead, the dramatic uptick in hospitalizations seen during the summer's delta surge was fueled by the highly transmissible variant spreading easily among mostly unvaccinated people, the CDC said.
The report, which analyzed COVID-19 hospitalization data from 14 states, also found that the proportion of people aged 18 to 49 hospitalized with delta increased "significantly" in July and August to 35.8% of all hospitalizations compared to 24.7% from January to June of this year. This was likely due to lower vaccination rates among younger people, the CDC said.
-ABC News' Sony Salzman
Pfizer vaccine highly effective in children 5-11
The Pfizer COVID-19 vaccine is nearly 91% effective against symptomatic illness in children ages 5-11, according to new data posted Friday ahead of a major FDA advisory committee meeting on Tuesday.
The vaccine also appeared safe, with none of the children experiencing a rare heart inflammation side effect known as myocarditis. If authorized in children 5-11, the Pfizer vaccine will be given at a smaller, one-third dose.
This efficacy estimate is from the company's clinical trial of 2,268 children in which some children got a placebo, and some children got the Pfizer vaccine. During the trial, 16 children who got the placebo shots developed COVID-19. Only three children who got the real vaccine developed COVID-19.
A small number of the children who were vaccinated and later developed COVID-19 experienced symptoms far fewer and milder than the children who were unvaccinated. For example, none of the vaccinated children developed a fever, while a majority of the unvaccinated children developed a fever along with other symptoms.
None of the children experienced serious adverse events. Many experienced typical symptoms like pain at the injection site, fatigue and headache.
The FDA's advisers will meet Tuesday to vote on whether to authorize the vaccine. From there, the FDA itself and the CDC will need to sign off -- a process that can take several days -- before shots could become available to children nationally.
- ABC News' Sony Salzman
CDC signs off on Moderna, J&J boosters
Hours after the unanimous vote from its independent advisory committee, the Centers for Disease Control and Prevention has signed off on recommending booster shots for the Moderna and Johnson & Johnson COVID-19 vaccines for certain populations.
CDC Director Rochelle Walensky recommended boosters for Pfizer and Moderna recipients with no preference on the brand, leaving that decision up to the individual.
People who are 65 and older, or individuals as young as 18 who have underlying medical conditions or live in high-risk or long-term care settings, are eligible to receive either a Pfizer or Moderna booster at least six months after their second shot, the CDC said.
The one-shot Johnson & Johnson vaccine is eligible to anyone aged 18 and up, at least two months after their initial dose, the CDC said.
-ABC News' Eric Strauss